MONOCLONAL ANTIBODIES TARGETING ION CHANNELS AND THERAPEUTIC POTENTIAL
- 1Université de Lille, France
- 2INSERM U1003 Laboratoire de Physiologie Cellulaire, France
Monoclonal antibodies (mAbs) represent a rapidly growing pharmaceutical class of protein drugs which becomes an important part of the precision therapy. mAbs are characterized by their high specificity and affinity for the target antigen which is mostly present on the cell surface. Ion channels are a large family of trans-membrane proteins that control ion transport across the cell membrane. They are involved in almost all biological processes in both health and disease and are widely considered as prospective targets. However, no antibody-based drug targeting ion channel has been developed so far that has progressed to clinical use. Thus, we provide a comprehensive review of the elaborated mAbs against ion channels, describe their mechanisms of action and discuss their therapeutic potential.
Keywords: Monoclonal antibody, ion channel, therapy, Mechanism, targeting
Received: 08 Nov 2018;
Accepted: 14 May 2019.
Edited by:Jean-François Desaphy, University of Bari Aldo Moro, Italy
Reviewed by:Theodore R. Cummins, School of Medicine, Indiana University Bloomington, United States
Ciro Leonardo Pierri, University of Bari Aldo Moro, Italy
Copyright: © 2019 LEHEN'KYI, Hantute-Ghesquier, Haustrate and Prevarskaya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. V'yacheslav LEHEN'KYI, Université de Lille, Lille, France, firstname.lastname@example.org